United States Tissue Diagnostics Market By Technology & Product (Immunohistochemistry, In situ Hybridization, Primary & Special Staining, Digital Pathology & Workflow, Anatomic Pathology), By End Use (Hospitals, Research Laboratories, Pharmaceutical Organizations, CRO), By Application (Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Cancer, Other Cancers), By Region, Competition, Forecast and Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 3.13 Billion
CAGR (2026-2031)	7.68%
Fastest Growing Segment	Digital Pathology
Largest Market	North-East
Market Size (2031)	USD 4.88 Billion

Market Overview

The United States Tissue Diagnostics Market will grow from USD 3.13 Billion in 2025 to USD 4.88 Billion by 2031 at a 7.68% CAGR. The United States Tissue Diagnostics Market encompasses products and services dedicated to the microscopic examination of tissue samples for disease detection and characterization, primarily utilizing techniques such as immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining. Key drivers supporting market expansion include the increasing prevalence of cancer, the rising adoption of personalized medicine requiring precise biomarker identification, and the growing demand for early and accurate disease diagnosis to improve patient outcomes.

These factors underscore the critical role of tissue diagnostics in healthcare. According to the American Cancer Society, in 2026, over 2.1 million new cancer diagnoses are projected in the United States, signifying a substantial and ongoing need for diagnostic capabilities. However, a significant challenge impeding market expansion is the persistent shortage of trained professionals, including skilled pathologists and laboratory technicians, which can strain diagnostic capacity and workflow efficiency.

Key Market Drivers

Rising cancer incidence and chronic disease burden fuel tissue diagnostics market
Rising cancer incidence and chronic disease burden significantly fuels the United States Tissue Diagnostics Market. The increasing prevalence of various cancers necessitates precise and timely tissue analysis for accurate diagnosis, staging, and treatment planning, creating a sustained demand for advanced diagnostic solutions, including immunohistochemistry and molecular profiling. These techniques are crucial for identifying specific biomarkers that guide personalized treatment strategies. According to the American Cancer Society, in January 2026, approximately 2.1 million new cancer cases are expected to be diagnosed in the US. This continuous rise in patient volumes requiring definitive diagnoses directly translates into an escalating need for sophisticated tissue diagnostic capabilities across hospitals and reference laboratories.

Digital pathology and imaging drive growth in tissue diagnostics
Advancements in digital pathology and imaging technologies represent another pivotal growth catalyst. These innovations enhance the efficiency and accuracy of pathology workflows by enabling remote analysis, AI-powered diagnostic assistance, and streamlined data management. The transition from traditional glass slides to digital images improves diagnostic consistency and reduces turnaround times, which are critical in a high-demand healthcare environment. According to Clinisys, in February 2026, as of January 2025, more than 50% of Mayo Clinic's surgical pathology cases, including all dermatology cases, were being digitized and interpreted by pathologists via digital pathology. Furthermore, the overall United States healthcare landscape, which encompasses the tissue diagnostics market, continues to see substantial activity, with, for example, according to the American Hospital Association, in 2025, total hospital expenses grew 7.5%. These technological leaps are instrumental in expanding diagnostic capacity and improving patient care pathways within the US healthcare system.

Download Free Sample Report

Key Market Challenges

Workforce shortages constrain diagnostic capacity and efficiency
A significant challenge impeding the United States Tissue Diagnostics Market expansion is the persistent shortage of trained professionals, including skilled pathologists and laboratory technicians. This scarcity directly hampers market growth by constraining diagnostic capacity and efficiency. The insufficient number of qualified personnel leads to increased turnaround times for tissue sample analysis, which can delay patient diagnoses and subsequent treatment initiation.

Staffing reductions strain workflows and slow adoption of advanced diagnostics
According to the College of American Pathologists, in 2025, eighteen percent of practices reported reduced pathologist staffing. This reduction stresses existing laboratory workflows and limits the ability of diagnostic centers to process the growing volume of tissue samples, particularly those driven by the increasing prevalence of cancer and demand for personalized medicine. The diminished workforce capacity also impacts the adoption and effective utilization of advanced diagnostic technologies, as there are fewer professionals available to operate and interpret results from these systems, ultimately slowing market expansion.

Key Market Trends

Expansion of Companion Diagnostics in Precision Oncology
The expanding application of companion diagnostics is a pivotal trend in the United States Tissue Diagnostics Market, driving personalized medicine by linking specific therapies to precise biomarker identification. These diagnostics enable clinicians to select the most effective treatments for patients, thereby enhancing therapeutic outcomes and mitigating adverse drug reactions. The integration of companion diagnostics into routine clinical practice ensures that patients receive targeted interventions based on their unique molecular profiles. For instance, according to CancerNetwork, in March 2026, the FDA approved PD-L1 IHC 22C3 pharmDx as a companion diagnostic for esophageal or gastroesophageal junction carcinoma, marking the eighth such indication for this test with pembrolizumab. This continuous expansion highlights their increasing importance in oncology and other therapeutic areas, fostering a more precise and patient-centric approach to healthcare.

Automation-Driven Transformation of Laboratory Workflows in Tissue Diagnostics
Another significant trend transforming the United States Tissue Diagnostics Market is the increasing automation in laboratory workflows. This shift addresses critical operational challenges such as the persistent shortage of skilled laboratory personnel and the rising volume of tissue samples requiring analysis. Automation, encompassing robotic systems for sample handling, slide preparation, and assay execution, enhances efficiency, reduces human error, and improves diagnostic throughput. These solutions streamline repetitive tasks, allowing laboratory professionals to focus on complex analyses and interpretation, thereby improving overall workflow and diagnostic consistency. According to a June 2026 survey published in Lab Manager, only one-third of life science laboratories continue to rely solely on manual operations. This indicates a clear movement towards integrating automated processes to optimize operations and meet the escalating demand for timely and accurate tissue diagnoses.

Segmental Insights

Growth Drivers in Digital Pathology
The Digital Pathology segment is currently the fastest-growing area within the United States Tissue Diagnostics Market. This accelerated growth is primarily attributed to continuous technological advancements, including sophisticated imaging systems and the increasing integration of artificial intelligence for enhanced analysis. These innovations significantly improve diagnostic accuracy, streamline laboratory workflows, and reduce turnaround times. Furthermore, the rising demand for telepathology services enables remote consultations and broadens access to specialized pathology expertise across geographical divides, addressing workforce distribution challenges. Regulatory support, exemplified by clearances from the U.S. Food and Drug Administration for digital pathology systems, further fosters widespread adoption and integration into standard clinical practice.

Regional Insights

North-East Leadership Driven by Infrastructure, Innovation, and Training
The North-East region leads the United States Tissue Diagnostics Market due to its robust healthcare infrastructure, encompassing extensive networks of hospitals and laboratories capable of performing a high volume of advanced diagnostic tests. The region benefits from a significant concentration of prominent academic institutions and leading pharmaceutical and biotechnology companies, fostering continuous innovation and collaborative research in tissue diagnostics, particularly for oncology applications. This environment supports the widespread adoption of advanced technologies like digital pathology and immunohistochemistry, further solidifying its dominant position through significant investments in healthcare and strong pathology training programs.

Recent Developments

• In June 2025, QIAGEN announced the expansion of its oncology diagnostics portfolio through strategic partnerships aimed at advancing minimal residual disease (MRD) testing in clinical trials. Collaborations with Tracer Biotechnologies and Foresight Diagnostics were established to develop companion diagnostics, specifically blood-based MRD tests for solid tumors on QIAGEN's QIAcuity digital PCR systems and a kit version of Foresight's CLARITY™ NGS assay for lymphoma. These partnerships were designed to support decentralized, non-invasive tools for precision medicine, strengthening QIAGEN's offerings within the United States Tissue Diagnostics Market for personalized cancer treatment.
• In March 2025, Epredia, a subsidiary of PHC Holdings Corporation, received U.S. FDA 510(k) clearance for its E1000 Dx Digital Pathology Solution. This solution was developed to enhance laboratory workflows in cancer diagnostics. The clearance signified a step forward in integrating digital technologies within the United States Tissue Diagnostics Market, offering laboratories improved tools for efficiency and accuracy in processing and analyzing tissue samples. This advancement aimed to support pathologists in providing timely and precise diagnoses, contributing to better patient care.
• In October 2024, Roche announced that its VENTANA Claudin 18 (43-14A) RxDx Assay received approval from the U.S. Food and Drug Administration (FDA). This immunohistochemistry (IHC) companion diagnostic was the first to be approved for determining CLDN18 protein expression in tumors of patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma. The approval allowed for the identification of patients who may be eligible for specific targeted treatments. This development directly impacted the United States Tissue Diagnostics Market by providing a new tool for precision oncology in gastric cancers and expanding diagnostic options for clinicians and patients.
• In February 2024, Roche entered into a collaboration agreement with PathAI to expand its digital pathology capabilities for companion diagnostics. PathAI, an artificial intelligence (AI)-powered technology company, began exclusively working with Roche Tissue Diagnostics to develop AI digital pathology algorithms for Roche's companion diagnostics business. These image analysis algorithms were intended for deployment on Roche's navify Digital Pathology platform, aiming for seamless integration into pathology laboratories, including those in the United States. This partnership was established to advance precision medicine by combining AI interpretation with companion diagnostics, thus increasing patient access to targeted treatments within the U.S. tissue diagnostics market.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Siemens Healthineers AG
• Bio-Rad Laboratories Inc.
• Agilent Technologies Inc.
• Leica Biosystems Nussloch GmbH
• Sakura Finetek Japan Co. Ltd.
• PerkinElmer Inc.

By Technology & Product	By End Use	By Application	By Region
Immunohistochemistry In situ Hybridization Primary & Special Staining Digital Pathology & Workflow Anatomic Pathology	Hospitals Research Laboratories Pharmaceutical Organizations CRO	Breast Cancer Non-Small Cell Lung Cancer Prostate Cancer Gastric Cancer Other Cancers	Northeast Midwest South West

Report Scope:

In this report, the United States Tissue Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Tissue Diagnostics Market, By Technology & Product:

• Immunohistochemistry
• In situ Hybridization
• Primary & Special Staining
• Digital Pathology & Workflow
• Anatomic Pathology

• United States Tissue Diagnostics Market, By End Use:

• Hospitals
• Research Laboratories
• Pharmaceutical Organizations
• CRO

• United States Tissue Diagnostics Market, By Application:

• Breast Cancer
• Non-Small Cell Lung Cancer
• Prostate Cancer
• Gastric Cancer
• Other Cancers

• United States Tissue Diagnostics Market, By Region:

• Northeast
• Midwest
• South
• West